Glenmark Pharmaceuticals S.a.

Sachin Sundarlal Chaudhari

Neelima Khairatkar-Joshi

Abraham Thomas

Sukeerthi Kumar

Indranil Mukhopadhyay

Ashok Bhausaheb Kadam

Sachin Vasantrao Dhone

Vidya Ganapati Kattige

Bipin Parsottam Kansagra

Girish Gudi

Venkata Ramana Yemireddy

Vishal Govindrao Deshmukh

Daisy Manish Shah

Malini Bajpai

Nisha Parag Patil

Rajendra Prakash Chikhale

Suresh Mahadev Kadam

Abhay Kulkarni

Vikram Mansingh Bhosale

Dinesh Pradeep Wale

Shailesh Ramesh Pardeshi

Sanjib Das

V S Prasada Rao Lingam

Vidya Ganpati Kattige

Prasada Rao V S Lingam

Thomas Abraham

Prashant Dilip Wadekar

Bharat G Adik

Neelima Khairatkar-joshi

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R, R, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

Aryl and heteroaryl ether compounds as ROR gamma modulators

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, X, M, R, R, R, R, m, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases and cancer. 

Bicyclic heteroaryl indole analogues useful as ROR gamma modulators

The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.

Treatment of respiratory disorders using TRPA1 antagonists

The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. 

2-amino-4-arylthiazole compounds as TRPA1 antagonists

The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. 

Fused pyrimidine-dione derivatives as TRPA1 modulators

The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. 

Fused pyrimidineone compounds as TRPV3 modulators

The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. 

Fused imidazole carboxamides as TRPV3 modulators

Growing community of inventors

Navi Mumbai, India

Sachin Sundarlal Chaudhari